RE:RE:Patient #16, #17 & #18
99942Apophis wrote: repost
99942Apophis wrote
Patient # 16 was announced treated in the news release dated March 25/2021 plus 90 days puts he or her at the end of June.
Patients # 17 & 18 were announced treated in the news release of April 27 plus 90 has them at the end of July.
Waiting with high hopes that these three parents will show CR (complete response) moving the average up and eventually meeting criteria for Fast Track and Breakthrough. Also looking for increases in enrolled/treated patients now that Covid-19 is moving into the rear-view mirror. In my biased opinion we are lining all the ducks up.
Hi Apophis...in my biased opinion, I agree ; ). I also think we have an advantage simply based on the fact that our ACT is a "first-in-class" form of treatment that is under investigation for BCG-unresponsive NMIBC....& there currently is no other treatment in use that uses this same mechanism of action to destroy this type of cancer. We have no similar competition to worry about at the moment. It is also encouraging to see a rising trend in the number of novel/first-in-class drug approvals by the FDA in the past 10-15 yrs...despite there being a relatively stable number of novel/first-in-class new drug applications. Not only do the ducks appear to be lining up, the line is looking straighter. Good luck.